CE
CELC.O
—
NASDAQ
Biotechnology & Medical Research
Celc.O
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
4,2B USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
-176,1 %
Net margin
—
Debt / equity
3,20
Beta
—
52w range
—
Volume
1,1k
Day range
$132,44–$138,26
Prev close
$134,26
Open
$133,26
Next earnings
—
Ex-dividend
—
TR 1Y
—
About
CELC.O is a biotechnology company focused on the development and commercialization of innovative therapies for the treatment of cancer and other serious diseases.
Business. CELC.O is a biotechnology and medical research company operating within the healthcare sector. The firm engages in pharmaceuticals and medical research activities, generating revenue through product sales. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not provided in the available data. Consequently, the company is described at the industry level without geographic or segmental breakdowns.
Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY12 analysts
11 buy1 hold0 sell
Avg 12m price target134,18
Analyst recommendations
12 analysts · consensus BuyBuy11
Hold1
Sell0
12-month price target
134,18
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
12 analysts · indicative
Ownership→
Jennison Associates LLC
largest disclosed fund holder
Profitability→
-176,1 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to CELC.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
CELC.O is a biotechnology and medical research company operating within the healthcare sector. The firm engages in pharmaceuticals and medical research activities, generating revenue through product sales. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not provided in the available data. Consequently, the company is described at the industry level without geographic or segmental breakdowns.
Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityPharmaceuticals & Medical Research
AI synthesis
GENERATEDCELC.O has a market capitalization of $6.74 billion and a price-to-book ratio of 67.03, indicating a high valuation relative to its book value. The company's liquidity position is characterized by $165.7 million in cash and equivalents, but it also carries $321.9 million in long-term debt, resulting in a debt-to-equity ratio of 3.2. The company's current ratio of 10.55 suggests a strong short-term liquidity position, with current assets significantly outpacing current liabilities.
The company's profitability is currently negative, with an operating loss of $172.2 million and a net loss of $177.0 million in the latest reporting period. Return on equity (ROE) is -1.76%, and return on assets (ROA) is -0.38%, both well below the industry median for biotechnology firms. These metrics indicate that the company is not generating returns for shareholders or efficiently utilizing its assets to generate profit.
CELC.O's revenue is concentrated in a few key therapeutic areas, with a primary focus on oncology. The company's geographic exposure is primarily in North America, where it has a significant presence in clinical trials and commercial operations. However, the company has limited revenue diversification across therapeutic areas and geographies, which could expose it to market-specific risks.
The company's growth trajectory is uncertain, with no clear revenue growth in the latest financial period. Analysts have provided a mean price target of $134.18, slightly below the current market price of $139.44, suggesting a cautious outlook. The company's capital expenditure of $249,000 is minimal, indicating a focus on maintaining operations rather than expanding capacity.
The company faces several risk factors, including its high debt-to-equity ratio and negative net cash position after subtracting total debt. These factors could limit its financial flexibility and increase its vulnerability to economic downturns or unexpected expenses. The risk of dilution is currently low, but the company's high valuation and negative cash flow could lead to future equity issuances to fund operations or reduce debt.
Recent events include the release of the latest financial snapshot, which highlights the company's ongoing financial challenges. The company has not disclosed any major new product launches or strategic partnerships in the recent period, and its focus remains on advancing its pipeline of oncology therapies.
Key takeaways
- CELC.O is a biotechnology company with a high valuation but negative profitability and significant debt.
- The company's liquidity position is strong in the short term but weak in the long term due to its high debt load.
- CELC.O's revenue is concentrated in oncology and North America, which could expose it to market-specific risks.
- Analysts have a cautious outlook, with a mean price target below the current market price.
- The company's high debt-to-equity ratio and negative net cash position are key risk factors.
- CELC.O's capital expenditure is minimal, indicating a focus on maintaining operations rather than expanding capacity.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$87,72
Market cap
$6.74B
Enterprise valueⓘ
$6.90B
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
67.0x
P / Tangible bookⓘ
67.0x
Tangible book
$100.6M
Net cashⓘ
-$156.1M
Current ratioⓘ
10.6
Debt / equityⓘ
3.2
ROAⓘ
-38.0%
ROEⓘ
-1.8%
Cash conversionⓘ
87.0%
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships1 disclosed relationship · 1 type · extracted from filings & disclosures
Partners1
Pfizer IncPFE.TOPartner99%Source ↗
Supply chain
Vendors → CELC ↔ Partners → Customers · click any node to drill
1 mention in 10-K0 from corporate websites0 from news dispatches
Updated 2026-06-24Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-3,99
Predicted surprise
0,00
Beat probability
45 %
Analysts
12
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-06 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -3,99 |
| Revenue | —no estimate | —no estimate | 44,6M USD |
| Operating income | —no estimate | —no estimate | -204,3M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Corporate eventM&A horizon
M&A probabilityconf 3 %
Probability
3 %
Base rate
3 %
Band
—
180-day horizon · target 2027-01-21 · 1,0× base rate
No acquirer candidates identified by the signal model.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution12 analysts
Strong buy5
Buy6
Hold1
Sell0
Strong sell0
12-month price target$134,18 · Median $135,00
Low $94,00High $165,00
Operating income · consensus-204,3M USD
EPS surprise
+5,1 %
reported vs consensus · beat
Revenue surprise
−100,0 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$94,00
Mean$134,18
Median$135,00
High$165,00
Spot$87,72
+53.0 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskMedium
Filing-based flags
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
ROE-176,1 %Bottom quartile
D/E3,20Bottom quartile
Cash Conv0,87Above median
Corporate actions / M&A
M&A probabilityconf —
Probability
3 %
Base rate
3 %
Band
Low
180-day horizon · target 2027-01-21 · 1,0× base rate
No acquirer candidates identified by the signal model.
Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net disposed 55 718 sh9 exercises5 insiders
- Director · Stock Option (right to buy) → Common StockDisposed 14 048 @ $10,69gift · 2026-06-10
- Director · Stock Option (right to buy) → Common StockDisposed 12 503 @ $10,69gift · 2026-06-10
- Director, Chief Science Officer · Stock Option (right to buy) → Common StockDisposed 1 000 @ $9,89exercise · 2026-06-02
- Director · Stock Option (right to buy) → Common StockDisposed 9 000 @ $5,10exercise · 2026-05-04
- Director · Stock Option (right to buy) → Common StockDisposed 3 000 @ $5,10exercise · 2026-03-31
- Director · Stock Option (right to buy) → Common StockDisposed 3 000 @ $5,50exercise · 2025-12-05
- Director · Stock Option (right to buy) → Common StockDisposed 250 @ $7,60exercise · 2025-12-04
- Director · Stock Option (right to buy) → Common StockDisposed 1 100 @ $14,83exercise · 2025-12-01
- Director · Stock Option (right to buy) → Common StockDisposed 3 900 @ $14,83exercise · 2025-11-20
- Director · Warrants (right to buy) → Common StockDisposed 4 672 @ $7,56exercise · 2025-09-11
- Director · Warrants (right to buy) → Common StockDisposed 3 245 @ $7,56exercise · 2025-09-11
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Source documents
- CELC.O Market data — financials · 2026-05-27
- Celcuity Inc Market data — analyst estimates · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,02 %$26M
- Investment Managers · as of 2026-03-310,02 %$0M
- Investment Managers · as of 2026-03-310,01 %$46M
- Investment Managers · as of 2026-03-310,01 %$154M
- Investment Managers · as of 2026-03-310,01 %$49M
- Investment Managers · as of 2026-03-310,01 %$102M
- Investment Managers · as of 2026-03-310,01 %$173M
- Investment Managers · as of 2026-03-310,01 %$34M
- Investment Managers · as of 2026-03-310,00 %$36M
- Investment Managers · as of 2026-03-310,00 %$25M
- Brokerage Firms · as of 2026-03-310,00 %$13M
- Investment Managers · as of 2025-12-310,00 %$227M
- Institutional Investor · as of 2026-03-310,00 %$11M
- Investment Managers · as of 2026-03-310,00 %$4M
- Institutional Investor · as of 2026-03-310,00 %$11M
- Funds · as of 2026-03-310,00 %$10M
- Investment Managers · as of 2026-03-310,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2024-06-300,00 %$24M
- Investment Managers · as of 2026-03-310,00 %$2M
- Brokerage Firms · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2024-12-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
Net selling4 buys · 15 sellsnet -$243K8 insiders · last 365d
- Director · Common StockOther 1 530 · 2026-06-05
- Director · Common StockOther 1 530 · 2026-06-05
- Director · Common StockOther 1 530 · 2026-06-05
- Director · Common StockOther 1 530 · 2026-06-05
- Director · Common StockOther 1 530 · 2026-06-05
- Director · Common StockOther 1 530 · 2026-06-05
- Director, Chief Science Officer · Common StockOther 1 000 @ $9,89$10K · 2026-06-02
- Director · Common StockOther 1 029 · 2026-05-19
- Director · Common StockSold 25 000 @ $140,68$3,5M · 2026-05-04
- Director · Common StockOther 9 000 @ $5,10$46K · 2026-05-04
- Director · Common StockSold 1 289 @ $137,00$177K · 2026-05-04
- Director · Common StockSold 550 @ $139,00$76K · 2026-05-04
- Director · Common StockSold 1 670 @ $139,58$233K · 2026-05-04
- Director · Common StockSold 2 301 @ $141,03$325K · 2026-05-04
- Director · Common StockSold 2 825 @ $142,04$401K · 2026-05-04
- Director · Common StockSold 365 @ $143,24$52K · 2026-05-04
- Director · Common StockOther 10 000 · 2026-04-09
- Director · Common StockOther 3 000 @ $5,10$15K · 2026-03-31
- Director · Common StockSold 2 325 @ $110,11$256K · 2026-03-31
- Director · Common StockSold 675 @ $110,83$75K · 2026-03-31
- Director · Common StockOther 215 · 2026-02-11
- Director · Common StockSold 20 000 @ $120,03$2,4M · 2026-01-27
- Director · Common StockOther 19 975 · 2025-12-15
- Director · Common StockOther 3 000 @ $5,50$16K · 2025-12-05
- Director · Common StockSold 1 490 @ $105,34$157K · 2025-12-05
Short positioning
11.2Mshares short+1.7% vs prior
5.67days to cover
59.7%short of daily vol
7.5Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
CELC.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskMedium
Net cash is negative after subtracting total debt.
Relationship graph
This companySectorPartners
Evidence & claims
From filings & derived data- Net income (YoY) (2025-12-31 vs 2024-12-31): -58.4%Derived (calculated)
- Return on equity (FY 2025-12-31): -176.1%Derived (calculated)
- Return on assets (FY 2025-12-31): -37.9%Derived (calculated)
- Current ratio (FY 2025-12-31): 10.55xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 3.64xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -0.4%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 636.0%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -33.9%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -33.9%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 30.9%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -83.6%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -52.0%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 39.1%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -13.0%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 90.3%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 182.6%Derived (calculated)
- Total liabilities (annual): USD 366MSEC XBRL filing
- Cash & equivalents (annual): USD 165.7MSEC XBRL filing
- R&D expense (annual): USD 145MSEC XBRL filing
- Operating income (annual): USD -172.19MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -4SEC XBRL filing
- Pre-tax income (annual): USD -177.04MSEC XBRL filing
- Total assets (annual): USD 466.56MSEC XBRL filing
- Current assets (annual): USD 465.66MSEC XBRL filing
Showing 24 of 54 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
2026-06-26 03:13 UTCHOLDER1 institutional position change flagged (1 major)
2026-06-25 03:10 UTCHOLDER1 institutional position change flagged (1 major)
2026-06-10 00:00 UTCINSIDER10 insider transactions — 2026-06 3 derivative
2026-06-10INSIDERMurphy Polly A. disposed of 14.0k sh Stock Option (right to buy) — Director
2026-06-10INSIDERBuller Richard E disposed of 12.5k sh Stock Option (right to buy) — Director
2026-06-05INSIDERNIGON RICHARD transacted 1.5k sh — Director
2026-06-05INSIDERMurphy Polly A. transacted 1.5k sh — Director
2026-06-05INSIDERDalvey David transacted 1.5k sh — Director
2026-06-05INSIDERROMP CHARLES R transacted 1.5k sh — Director
2026-06-05INSIDERFurcht Leo transacted 1.5k sh — Director
2026-06-05INSIDERBuller Richard E transacted 1.5k sh — Director
2026-06-02INSIDERLaing Lance G. transacted 1.0k sh — Director, Chief Science Officer ~$10k
2026-06-02INSIDERLaing Lance G. disposed of 1.0k sh Stock Option (right to buy) — Director, Chief Science Officer
2026-05-19 00:00 UTCINSIDER10 insider transactions — 2026-05 · net sell $4.7M 1 derivative
2026-05-19INSIDERBuller Richard E transacted 1.0k sh — Director
2026-05-04INSIDERDalvey David sold 25.0k sh — Director ~$3.52M
2026-05-04INSIDERBuller Richard E transacted 9.0k sh — Director ~$46k
2026-05-04INSIDERBuller Richard E sold 1.3k sh — Director ~$177k
2026-05-04INSIDERBuller Richard E sold 550 sh — Director ~$76k
2026-05-04INSIDERBuller Richard E sold 1.7k sh — Director ~$233k
2026-05-04INSIDERBuller Richard E sold 2.3k sh — Director ~$325k
2026-05-04INSIDERBuller Richard E sold 2.8k sh — Director ~$401k
2026-05-04INSIDERBuller Richard E sold 365 sh — Director ~$52k
2026-05-04INSIDERBuller Richard E disposed of 9.0k sh Stock Option (right to buy) — Director
2026-04-09 00:00 UTCINSIDER1 insider transaction — 2026-04
2026-04-09INSIDERNIGON RICHARD transacted 10.0k sh — Director
2026-03-31 00:00 UTCINSIDER4 insider transactions — 2026-03 · net sell $316k 1 derivative
2026-03-31INSIDERBuller Richard E transacted 3.0k sh — Director ~$15k
2026-03-31INSIDERBuller Richard E sold 2.3k sh — Director ~$256k
Showing the 40 most recent of 60 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage